Compare VanEck Rare Earth/Strategic Metals (REMX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Viatris Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $71.1, while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc pays a 2.73% dividend while VanEck Rare Earth/Strategic Metals pays none, and Viatris Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $17.59 |
52-Week Low | $49.22 | $8.74 |
Market Cap | — | $20.50B |
Enterprise Value | — | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $69.85, down 3.88% amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals against zero bullish, though oscillators show some buying opportunity with RSI readings in oversold territory. Recent news highlights ongoing geopolitical tensions around rare earth supply chains, with China's export controls and US efforts to secure critical minerals driving volatility in the sector.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China concentration risk. While strategic metals demand remains strong for technology and defense applications, REMX is best suited as a satellite holding for aggressive portfolios due to its specialized nature and geopolitical sensitivities.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
